CoChat

Clinical trials with anti‐angiogenic agents in hematological malignancies

Open access
Medinger, Michael, Mross, Klaus · 2010 · Journal of Angiogenesis Research

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Abstract

New blood vessel formation (angiogenesis) is not only essential for the growth of solid tumors but there is also emerging evidence that progression of hematological malignancies like multiple myeloma, acute leukemias, and myeloproliferative neoplasms, also depends on new blood vessel formation. Anti-angiogenic strategies have become an important therapeutic modality for solid tumors. Several anti-angiogenic agents targeting angiogenesis-related pathways like monoclonal antibodies, receptor tyrosine kinase inhibitors, immunomodulatory drugs, and proteasome inhibitors have been entered clinical trials or have been already approved for the treatment of hematological malignancies as well and in some instances these pathways have emerged as promising therapeutic targets. This review summarizes recent advances in the basic understanding of the role of angiogenesis in hematological malignancies and clinical trials with novel therapeutic approaches targeting angiogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2040-2384-2-10

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Therapeutic strategies to target the VEGF/VEGF receptor system. VEGF, vascular endothelial growth factor.
Figure 1 Therapeutic strategies to target the VEGF/VEGF receptor system. VEGF, vascular endothelial growth factor.CC BY · PubMed Central
Figure 2 Modes of action of IMiDs. IL-6, interleukin-6; IMiDs, immunomodulatory drugs; NK cells, Natural killer cells; Th1 cells, T helper 1 cells; TNFα, tumor necrosis factor alpha; Treg, regulatory T cells; VEGF, vascular endothelial growth factor.
Figure 2 Modes of action of IMiDs. IL-6, interleukin-6; IMiDs, immunomodulatory drugs; NK cells, Natural killer cells; Th1 cells, T helper 1 cells; TNFα, tumor necrosis factor alpha; Treg, regulatory T cells; VEGF, vascular endothelial growth factor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Roccaro AM Hideshima T Raje N Kumar S Ishitsuka K Yasui H Shiraishi N Ribatti D Nico B Vacca A Dammacco F Richardson PG Anderson KC Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells Cancer Research 2006 66 184 191 10.1158/0008-5472.CAN-05-1195 16397231 · DOI · Paper page

Cited by

See all 40

Metadata

Authors
Medinger, M., & Mross, K.
Affiliations
University of Freiburg (DE)
Corresponding author
Mross, Klaus
Venue
Journal of Angiogenesis Research
Published
2010
Volume
2
Issue
1
Pages
10
ISSN
2040-2384 (ISSN-L)
OpenAlex
W1987797098
Cited by
40
References
106
Citations by year
2026: 1 · 2024: 3 · 2023: 1 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 4 · 2015: 2 · 2014: 7 · 2012: 1
FWCI
0.91
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Vascular Cell (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Vascular Tumors and Angiosarcomas
Keywords
angiogenesis, angiogenesis inhibitors, hematologic malignancies, multiple myeloma, acute leukemia, myeloproliferative neoplasms, monoclonal antibodies, receptor tyrosine kinase inhibitors, immunomodulators, proteasome inhibitors, clinical trials

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.